Trial Profile

A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants With Propionic Acidemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA-3927 (Primary)
Indications Propionic acidaemia
Focus Adverse reactions; Biomarker; First in man; Therapeutic Use
Acronyms Paramount
Sponsors Moderna Therapeutics

Most Recent Events

28 Mar 2025 Planned End Date changed from 6 Jan 2027 to 31 Jan 2026.
28 Mar 2025 Planned primary completion date changed from 5 Mar 2025 to 31 Jan 2026.
13 Jan 2025 According to a Moderna Therapeutics media release, The Company began generating registrational trial data in 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com